Alcon Inc. filed an investor presentation with the U.S. Securities and Exchange Commission on November 3, 2025 to support its proposed acquisition of STAAR Surgical Company.
The presentation details a $1.5 billion deal in which Alcon will purchase STAAR’s common stock for $28 per share in cash, representing a 59% premium to STAAR’s 90‑day volume‑weighted average price and a 51% premium to the August 4, 2025 closing price.
The acquisition, announced on August 5, 2025, is intended to complement Alcon’s laser vision‑correction business and broaden its myopia‑treatment portfolio; the transaction is expected to be accretive to earnings in year two.
STAAR’s Q1 2025 sales declined 45% to $42.6 million from $77.4 million in Q1 2024, largely due to weak consumer spending in China; Alcon plans to leverage STAAR’s EVO ICL technology to stabilize operations and expand market reach.
Alcon’s Q2 2025 results showed net sales of $2.6 billion, up 4% year‑over‑year, with a core operating margin of 19.1%, down 70 basis points; the Vision Care segment outperformed the Surgical segment.
The transaction is expected to close within six to twelve months, subject to customary closing conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.